{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T09:31:59Z","timestamp":1740130319896,"version":"3.37.3"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T00:00:00Z","timestamp":1690329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>In men undergoing upfront active surveillance, predictors of adverse pathology in radical prostatectomy specimens, including intraductal carcinoma of the prostate and cribriform patterns, remain unknown. Therefore, we aimed to examine whether adverse pathology in radical prostatectomy specimens could be predicted using preoperative patient characteristics.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We re-reviewed available radical prostatectomy specimens from 1035 men prospectively enrolled in the PRIAS-JAPAN cohort between January 2010 and September 2020. We defined adverse pathology on radical prostatectomy specimens as Gleason grade group \u22653, pT stage \u22653, pN positivity or the presence of intraductal carcinoma of the prostate or cribriform patterns. We also examined the predictive factors associated with adverse pathology.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>All men analyzed had Gleason grade group 1 specimens at active surveillance enrolment. The incidence of adverse pathologies was 48.9% (with intraductal carcinoma of the prostate or cribriform patterns, 33.6%; without them, 15.3%). The addition of intraductal carcinoma of the prostate or cribriform patterns to the definition of adverse pathology increased the incidence by 10.9%. Patients showing adverse pathology with intraductal carcinoma of the prostate or cribriform patterns had lower biochemical recurrence-free survival (log-rank P\u00a0=\u00a00.0166). Increasing age at active surveillance enrolment and before radical prostatectomy was the only predictive factor for adverse pathology (odds ratio: 1.1, 95% confidence interval: 1.02\u20131.19, P\u00a0=\u00a00.0178; odds ratio: 1.12, 95% confidence interval: 1.02\u20131.22, P\u00a0=\u00a00.0126).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Increasing age could be a predictive factor for adverse pathology. Our findings suggest that older men could potentially derive advantages from adhering to the examination schedule in active surveillance.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jjco\/hyad088","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T06:51:18Z","timestamp":1690440678000},"page":"984-990","source":"Crossref","is-referenced-by-count":2,"title":["Increasing age predicts adverse pathology including intraductal carcinoma of the prostate and cribriform patterns in deferred radical prostatectomy after upfront active surveillance for Gleason grade group 1 prostate cancer: analysis of prospective observational study cohort"],"prefix":"10.1093","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3884-8915","authenticated-orcid":false,"given":"Yoichiro","family":"Tohi","sequence":"first","affiliation":[{"name":"Department of Urology , Faculty of Medicine, , Kagawa , Japan"},{"name":"Kagawa University , Faculty of Medicine, , Kagawa , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryou","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology , Faculty of Medicine, , Kagawa , Japan"},{"name":"Kagawa University , Faculty of Medicine, , Kagawa , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuma","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Urology , Faculty of Medicine, , Kagawa , Japan"},{"name":"Kagawa University , Faculty of Medicine, , Kagawa , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jimpei","family":"Miyakawa","sequence":"additional","affiliation":[{"name":"Department of Urology , Graduate School of Medicine, , Tokyo , Japan"},{"name":"The University of Tokyo , Graduate School of Medicine, , Tokyo , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuji","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Renal and Genito-Urinary Surgery , Graduate School of Medicine, , Hokkaido , Japan"},{"name":"Hokkaido University , Graduate School of Medicine, , Hokkaido , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichiro","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Urology, Jikei University School of Medicine , Tokyo , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Mitsuzuka","sequence":"additional","affiliation":[{"name":"Department of Urology, Tohoku University Graduate School of Medicine , Miyagi , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Inokuchi","sequence":"additional","affiliation":[{"name":"Department of Urology , Graduate School of Medical Sciences, , Fukuoka , Japan"},{"name":"Kyushu University , Graduate School of Medical Sciences, , Fukuoka , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"Matsumura","sequence":"additional","affiliation":[{"name":"Department of Urology, National Hospital Organization Shikoku Cancer Center , Ehime , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichiro","family":"Shiga","sequence":"additional","affiliation":[{"name":"Division of Urology, Harasanshin Hospital , Fukuoka , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1045-1978","authenticated-orcid":false,"given":"Hirohito","family":"Naito","sequence":"additional","affiliation":[{"name":"Department of Urology, Kurashiki Central Hospital , Okayama , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuo","family":"Kohjimoto","sequence":"additional","affiliation":[{"name":"Department of Urology, Wakayama Medical University , Wakayama , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norihiko","family":"Kawamura","sequence":"additional","affiliation":[{"name":"Department of Urology, Osaka International Cancer Institute , Osaka , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaharu","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Urology, Saitama Cancer Center , Saitama , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shusuke","family":"Akamatsu","sequence":"additional","affiliation":[{"name":"Department of Urology, Kyoto University Graduate School of Medicine , Kyoto , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Terada","sequence":"additional","affiliation":[{"name":"Department of Urology , Faculty of Medicine, , Miyazaki , Japan"},{"name":"University of Miyazaki , Faculty of Medicine, , Miyazaki , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Miyazawa","sequence":"additional","affiliation":[{"name":"Department of Urology, Gunma University Graduate School of Medicine , Gunma , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2988-1860","authenticated-orcid":false,"given":"Shintaro","family":"Narita","sequence":"additional","affiliation":[{"name":"Department of Urology, Akita University School of Medicine , Akita , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reiji","family":"Haba","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology , Faculty of Medicine, , Kagawa , Japan"},{"name":"Kagawa University , Faculty of Medicine, , Kagawa , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9266-782X","authenticated-orcid":false,"given":"Mikio","family":"Sugimoto","sequence":"additional","affiliation":[{"name":"Department of Urology , Faculty of Medicine, , Kagawa , Japan"},{"name":"Kagawa University , Faculty of Medicine, , Kagawa , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,7,26]]},"reference":[{"key":"2023100417320215100_ref1","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate Cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent","volume":"79","author":"Mottet","year":"2021","journal-title":"Eur Urol"},{"key":"2023100417320215100_ref2","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.juro.2018.01.002","article-title":"Clinically localized prostate cancer: AUA\/ASTRo\/SUO guideline. Recommended approaches and details of specific care options","volume":"199","author":"Sanda","year":"2018","journal-title":"J Urol"},{"key":"2023100417320215100_ref3","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1001\/jama.2018.19941","article-title":"Use of active surveillance or watchful waiting for low-risk prostate cancer and management trends across risk groups in the United States, 2010\u20132015","volume":"321","author":"Mahal","year":"2019","journal-title":"JAMA"},{"key":"2023100417320215100_ref4","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1001\/jamaoncol.2016.3600","article-title":"Uptake of active surveillance for very-low-risk prostate cancer in Sweden","volume":"3","author":"Loeb","year":"2017","journal-title":"JAMA Oncol"},{"volume-title":"Network NCC NCCN clinical practice guidelines in oncology: Prostate cancer","key":"2023100417320215100_ref5"},{"key":"2023100417320215100_ref6","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ejca.2016.07.012","article-title":"Prostate cancer outcomes of men with biopsy Gleason score 6 and 7 without cribriform or intraductal carcinoma","volume":"66","author":"Kweldam","year":"2016","journal-title":"Eur J Cancer"},{"key":"2023100417320215100_ref7","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1097\/PAS.0b013e3182a02169","article-title":"Architectural heterogeneity and cribriform growth predict adverse clinical outcome for Gleason grade 4 prostatic adenocarcinoma","volume":"37","author":"Dong","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"2023100417320215100_ref8","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1002\/pros.22786","article-title":"Prognostic value of intraductal carcinoma of the prostate in radical prostatectomy specimens","volume":"74","author":"Kimura","year":"2014","journal-title":"Prostate"},{"key":"2023100417320215100_ref9","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1007\/s10147-020-01841-4","article-title":"Grade group 2 (10% \u2265 GP4) patients have very similar malignant potential with grade group 1 patients, given the risk of intraductal carcinoma of the prostate","volume":"26","author":"Kato","year":"2021","journal-title":"Int J Clin Oncol"},{"key":"2023100417320215100_ref10","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.eururo.2016.06.007","article-title":"A decade of active surveillance in the PRIAS study: an update and evaluation of the criteria used to recommend a switch to active treatment","volume":"70","author":"Bokhorst","year":"2016","journal-title":"Eur Urol"},{"key":"2023100417320215100_ref11","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.3390\/cancers14153558","article-title":"Adverse pathological findings at radical prostatectomy following active surveillance: results from the Movember GAP3 cohort","volume":"14","author":"Marenghi","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2023100417320215100_ref12","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1007\/s00345-020-03394-7","article-title":"Predictors of adverse pathology on radical prostatectomy specimen in men initially enrolled in active surveillance for low-risk prostate cancer","volume":"39","author":"Bj\u00f6rnebo","year":"2021","journal-title":"World J Urol"},{"key":"2023100417320215100_ref13","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.juro.2018.04.078","article-title":"Long-term outcomes after deferred radical prostatectomy in men initially treated with active surveillance","volume":"200","author":"Godtman","year":"2018","journal-title":"J Urol"},{"key":"2023100417320215100_ref14","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/JU.0000000000000247","article-title":"Evaluating the safety of active surveillance: outcomes of deferred radical prostatectomy after an initial period of surveillance","volume":"202","author":"Balakrishnan","year":"2019","journal-title":"J Urol"},{"key":"2023100417320215100_ref15","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/j.eururo.2007.05.011","article-title":"Prospective validation of active surveillance in prostate cancer: the PRIAS study","volume":"52","author":"Bergh","year":"2007","journal-title":"Eur Urol"},{"key":"2023100417320215100_ref16","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1007\/s10147-020-01761-3","article-title":"The impact of complications after initial prostate biopsy on repeat protocol biopsy acceptance rate. Results from the prostate cancer research international: active surveillance JAPAN study","volume":"25","author":"Tohi","year":"2020","journal-title":"Int J Clin Oncol"},{"key":"2023100417320215100_ref17","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s10147-022-02277-8","article-title":"Clinical outcomes of intraductal carcinoma or cribriform in radical prostatectomy specimens of men opting for active surveillance: data from the PRIAS-JAPAN study","volume":"28","author":"Tohi","year":"2023","journal-title":"Int J Clin Oncol"},{"key":"2023100417320215100_ref18","first-page":"1056","article-title":"Impact of adherence to criteria on oncological outcomes of radical prostatectomy in patients opting for active surveillance: data from the PRIAS-JAPAN study","volume":"52","author":"Tohi","year":"2022","journal-title":"Jpn J Clin Oncol"},{"key":"2023100417320215100_ref19","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1097\/00000478-199607000-00003","article-title":"Spread of adenocarcinoma within prostatic ducts and acini. Morphologic and clinical correlations","volume":"20","author":"McNeal","year":"1996","journal-title":"Am J Surg Pathol"},{"issue":"69","key":"2023100417320215100_ref20","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.eururo.2015.08.052","article-title":"PI-RADS prostate imaging \u2013 reporting and data system: 2015, version 2","volume":"2","author":"Weinreb","year":"2016","journal-title":"Eur Urol"},{"key":"2023100417320215100_ref21","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.urology.2021.05.044","article-title":"Association of age with risk of adverse pathological findings in men undergoing delayed radical prostatectomy following active surveillance","volume":"155","author":"Calle","year":"2021","journal-title":"Urology"},{"key":"2023100417320215100_ref22","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.juro.2018.08.023","article-title":"Older age predicts biopsy and radical prostatectomy grade reclassification to aggressive prostate cancer in men on active surveillance","volume":"201","author":"Druskin","year":"2019","journal-title":"J Urol"},{"key":"2023100417320215100_ref23","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.euf.2020.02.008","article-title":"Clinical-genomic characterization unveils more aggressive disease features in elderly prostate cancer patients with low-grade disease","volume":"7","author":"Goldberg","year":"2021","journal-title":"Eur Urol Focus"},{"key":"2023100417320215100_ref24","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/pros.1046","article-title":"High-grade prostate cancer is associated with low serum testosterone levels","volume":"47","author":"Schatzl","year":"2001","journal-title":"Prostate"},{"key":"2023100417320215100_ref25","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s00345-014-1453-8","article-title":"Should inclusion criteria for active surveillance for low-risk prostate cancer be more stringent? From an interim analysis of PRIAS-JAPAN","volume":"33","author":"Sugimoto","year":"2015","journal-title":"World J Urol"},{"key":"2023100417320215100_ref26","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.urology.2014.07.003","article-title":"Prediction of long-term other-cause mortality in men with early-stage prostate cancer: results from the prostate cancer outcomes study","volume":"85","author":"Daskivich","year":"2015","journal-title":"Urology"},{"key":"2023100417320215100_ref27","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.eururo.2012.10.002","article-title":"Natural history of early, localized prostate cancer: a final report from three decades of follow-up","volume":"63","author":"Popiolek","year":"2013","journal-title":"Eur Urol"},{"key":"2023100417320215100_ref28","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/pros.23926","article-title":"Correlation between cribriform\/intraductal prostatic adenocarcinoma and percent Gleason pattern 4 to a 22-gene genomic classifier","volume":"80","author":"Taylor","year":"2020","journal-title":"Prostate"},{"key":"2023100417320215100_ref29","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.eururo.2014.08.007","article-title":"Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis","volume":"67","author":"Risbridger","year":"2015","journal-title":"Eur Urol"},{"key":"2023100417320215100_ref30","doi-asserted-by":"crossref","first-page":"629","DOI":"10.3390\/jpm13040629","article-title":"Active surveillance for prostate cancer: past, current, and future trends","volume":"13","author":"Vos","year":"2023","journal-title":"J Pers Med"},{"key":"2023100417320215100_ref31","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1200\/JCO.2009.25.7311","article-title":"Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program","volume":"28","author":"Ross","year":"2010","journal-title":"J Clin Oncol"},{"key":"2023100417320215100_ref32","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1016\/j.juro.2010.12.042","article-title":"The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer","volume":"185","author":"Whitson","year":"2011","journal-title":"J Urol"},{"key":"2023100417320215100_ref33","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/j.1464-410X.2008.08116.x","article-title":"Prostate-specific antigen (PSA) kinetics in untreated, localized prostate cancer: PSA velocity vs PSA doubling time","volume":"103","author":"Ng","year":"2009","journal-title":"BJU Int"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/53\/10\/984\/51848981\/hyad088.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/53\/10\/984\/51848981\/hyad088.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T17:33:11Z","timestamp":1696440791000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/53\/10\/984\/7231524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,26]]},"references-count":33,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,7,26]]},"published-print":{"date-parts":[[2023,10,4]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyad088","relation":{},"ISSN":["1465-3621"],"issn-type":[{"type":"electronic","value":"1465-3621"}],"subject":[],"published-other":{"date-parts":[[2023,10]]},"published":{"date-parts":[[2023,7,26]]}}}